Hints and tips:
...BioNTech and Pfizer have said the patents are invalid....
...JPMorgan and law firm Ropes & Gray advised Pfizer, while Centerview Partners and law firm Sullivan & Cromwell advised Biohaven....
...Two doses of the BioNTech/Pfizer vaccine provide 70 per cent protection against being admitted to hospital with the Omicron coronavirus variant, according to the first real-world analysis of protection against...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...His mother was a Time Inc executive, and his father a Washington diplomat who worked for the US Agency for International Development....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...But sales of the Ariens Ikon XD, featuring 20-inch tyres, a V-twin Kawasaki engine and ergonomic plush seat, have surged in the US during the pandemic....
...Hope for sickle cell Victoria Gray had been ill for all of her 34 years....
...We did this two years ago when Ian Read, the Scottish-born accountant turned businessman, announced his plans to step down as chief executive of pharmaceuticals group Pfizer....
...Mr Greene has also worked on many complex M&A deals, including pharmaceutical company Mylan’s pending $50bn combination with Upjohn, a division of Pfizer....
...Pfizer on Monday added a further $10bn share repurchase authorisation to the $6.4bn that remained under its previous programme....
...In place of black, gray, and blue, Uber is embracing bright colours, and lots of them....
...Alistair Gray EARNINGS AIG Q3 $1.04 ($1.21) Imperial’s independent aim Investors will be looking for growth in Imperial Tobacco’s US brands when it reports full-year earnings....
...Pfizer was advised by Guggenheim Securities, JPMorgan and Lazard, with legal assistance from Ropes & Gray and Clifford Chance....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Also, Louise Gray....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...scenario for 2010, though most gave the V-shaped version the shortest shrift. More inclined to fade the extremes, than out and out pessimistic....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
International Edition